Blair HA

No ORCID on file · 2 papers in corpus
review 2024
Drugs ·doi:10.1007/s40265-024-02050-3
review 2024
Drugs ·doi:10.1007/s40265-024-02018-3

An oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as norethindrone) acetate [Myfembree® (USA); Ryeqo® (EU)] (hereafter referred to as relugolix combination therapy) has been approved in the USA for the managem…